메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

SHANGHAI, Dec. 9, 2025 -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma. Golidocitinib Newly diagnosed PTCL Two dose regimes of golidocitinib combined with CHOP have been explored for th
- 김갑성 기자
- 2025-12-09 18:00
From Mobile phone to the Green: Adak Golf Reinvents Club Maintenance with the World's First Diamond-infused Groove Sharpener & Cleaner

[ 메디채널 황정호 기자 ] High-precision OLED display polishing technology meets the fairway, setting a new standard for backspin performance and club longevity. SEOUL, South Korea, Dec. 9, 2025 -- Already a best-seller in South Korea, Adak Golf is now rapidly expanding into the U.S. and Japanese markets, bringing industrial-grade technology to everyday golfers looking for reliable performance and equipment longevity. For years, golfers seeking to restore spin to their wedges have had limited—and often risky—options. Traditional groove tools, from sharpened awls to metal cutte
- 황정호 기자
- 2025-12-09 17:42
Jiangyin Concludes Golden Autumn Investment Month with 208 Projects Totaling RMB68 Billion

JIANGYIN, China, Dec. 9, 2025 -- The 2025 Jiangyin Symposium on Economic and Trade Cooperation was held on December 6, hosted by the Jiangyin Municipal Committee and Government. Marking the culmination of this year's Golden Autumn Investment Month, which featured more than 50 promotional events, the symposium resulted in the signing of 208 projects with a combined investment value of RMB68 billion. Since the start of the 14th Five-Year Plan period, Jiangyin has secured 321 major industrial projects, each valued at more than RMB100 million, representing a total investment of RMB262.7 billion.
- 황정호 기자
- 2025-12-09 17:37
Zoomlion's Agricultural Machinery Gains Ground Across Kenya's Fields

NAIROBI, Kenya, Dec. 9, 2025 -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"; 1157.HK) is helping Kenyan farmers navigate the country's shifting seasons, where heavy rains turn fields to mud and the dry months leave soil unworkable. In Nakuru, Zoomlion's agricultural machinery is increasing land productivity and giving farmers tools suited to local field conditions. Around 70 percent of Kenya's population depends on farming but progress has been stymied by limited mechanization. Extreme weather strains traditional labor, and used equipment often falls short
- 황정호 기자
- 2025-12-09 16:52
Xtep-Athletes Sweep Full Marathon Podiums at Techcombank Ho Chi Minh City International Marathon

[ 메디채널 황정호 기자 ] A Medal Haul: Xtep Athletes Secure 6 Golds, 2 Silver, 2 Bronzes HO CHI MINH CITY, Vietnam, Dec. 9, 2025 -- Attracting 23,000 runners globally, the 8th Edition of the Techcombank Ho Chi Minh City International Marathon successfully launched on December 7. After an intense competition, Xtep-sponsored elite athletes delivered a dominant performance. In the men's full marathon, Ethiopian international elites swept the podium: Ayalew Seleshi Simaneh claimed victory with an impressive time of 02:23:12, followed by Wondale Melsew Baye (02:23:23) and Kebede Leta Girma (02:23:
- 황정호 기자
- 2025-12-09 16:02
NUS scientists create microneedle system to deliver biofertiliser directly into plants, boosting growth with less waste

[ 메디채널 황정호 기자 ] A dissolving patch delivers beneficial microbes into leaves and stems, speeding growth in vegetables while using over 15 per cent less biofertiliser than soil application SINGAPORE, Dec. 9, 2025 -- Researchers at the National University of Singapore (NUS) have developed dissolving microneedle patches that deliver living "biofertiliser" straight into plant tissue. In greenhouse tests, Choy Sum and Kale grew faster — by shoot biomass, leaf area and height — while using over 15 per cent less biofertiliser than standard soil inoculation. The approach poin
- 황정호 기자
- 2025-12-09 16:01
VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 -- In a move that reflects the shifting expectations of Malaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launched CareConnect Suite, a new digital ecosystem aimed at closing long-standing gaps in employee benefits for small and medium enterprises (SMEs). The foundation of CareConnect Suite is the combination of EzPA — VSure's uniquely curated, affordable and accessible PA protection with hospital income benefit — and FutureK, HEYDOC Health's digitally integrated outpatient care model.
- 김갑성 기자
- 2025-12-09 15:58
Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 -- As the world's first country to be prescribed for its health benefits, Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy. The Swedish Prescription video shows how it works. With interest in "northern lights travel" on the rise and 61% of travelers naming the aurora borealis as the top natural phenomenon they want to experience, the timing couldn't be better. A rare solar maximum is underway, making aurora displays brighter, more frequent and
- 김갑성 기자
- 2025-12-09 15:53
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

HONG KONG, Dec. 9, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as neoadjuvant therapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was presented at the 2025 ESMO Asia Congress. Currently, Akeso is running the pivotal Phase III study (AK104-310/COMPASSION-33) investigating cadonilimab combined with the SOX regimen for perio
- 김갑성 기자
- 2025-12-09 15:50
Hanwha Life CGO Dong-Won Kim Reaffirms Commitment to Strengthening South Korea-UAE Financial Cooperation at ADFW 2025

[ 메디채널 황정호 기자 ] - "Advancing the South Korea–UAE '100-Year Partnership' Through Finance," the CGO said in his Opening Address- Unveils Vision for Building a Next-Generation Global Financial Ecosystem With Abu Dhabi- Highlights Future Agendas Including Co-Investments and Digital Asset Platform Development SEOUL, South Korea and ABU DHABI, UAE, Dec. 8, 2025 -- Dong-Won Kim, Chief Global Officer (CGO) at Hanwha Life, delivered the opening address at the Global Markets Summit during Abu Dhabi Finance Week (ADFW) 2025 on Dec. 8, highlighting the importance of South Korea–UAE coo
- 황정호 기자
- 2025-12-09 15:29

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 16시 00분